Neuroimaging Tracks the Progress of Cognitive Decline

FEATURED SEARCH TERM:    mri change AND cognitive therapy



Sporadic cerebral amyloid angiopathy, a common age-related cerebral small vessel disease, is an important contributor to cognitive decline. Recent advances in neuroimaging have provided a new window into the hemorrhagic and ischemic features of the disease, characterized by progressive deposition of cerebral amyloid-β. Molecular imaging of amyloid-β may improve the ability to detect the disease and define its true prevalence, state the authors of the report below.


RESULT: Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum
Journal of Neurology, Neurosurgery, & Psychiatry | Feb 1, 2012 (FREE FULL TEXT)


This classic study details how cognitive decline and brain volume loss are the signatures of cerebral amyloid-β peptide deposition in cognitively healthy older people. In a 23-year-long longitudinal study, in vivo measurement of cerebral amyloidosis revealed atrophy in specific regions of the brain and a decline in multiple cognitive domains before the clinical diagnosis of Alzheimer disease.


RESULT: Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-β Peptide Deposition Identified With Pittsburgh Compound B
Archives of Neurology | Dec 1, 2009 (FREE FULL TEXT)